Form 8-K - Current report:
SEC Accession No. 0001438533-25-000012
Filing Date
2025-03-17
Accepted
2025-03-17 16:57:21
Documents
13
Period of Report
2025-03-17
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20250317.htm   iXBRL 8-K 38929
  Complete submission text file 0001438533-25-000012.txt   168761

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20250317.xsd EX-101.SCH 1782
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20250317_lab.xml EX-101.LAB 22804
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20250317_pre.xml EX-101.PRE 13046
15 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20250317_htm.xml XML 2830
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 25745381
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)